Boenning & Scattergood Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Neutral
More News related to ONXX
- S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
- Baird Comments on Onyx Pharmaceuticals (ONXX) On China NDRL Update
- Onyx Pharmaceuticals Announces December 2009 Investor Events
- Notable Mergers and Acquisitions of the Day 11/16: CSCO, MOT, TTMI, ONXX
- Onyx Pharmaceuticals (ONXX) Completes Acquisition of Proteolix
More News related to New Coverage
- A.C. Moore (ACMR) Hires Richard Arthur as VP of Marketing and Advertising
- Cascade Microtech's (CSCD) CEO, Wild, to Resign
- Qualcomm (QCOM) Appoints Rich Sulpizio to President and CEO of QCOM Enterprise Services
- ConocoPhillips (COP) Promotes Larry Archibald to SVP, Exploration and Business Development
- GM's Chairman, Ed Whitacre, has said that the search for a CEO could take as long as a year
Boenning & Scattergood initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with a Neutral.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.92Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
